Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of sigvotatug vedotin in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), breast cancer and 9 more (5 arms), sponsored by Pfizer. Primary endpoints: Adverse Events up to 3 years, Laboratory Abnormalities up to 3 years and 1 more. Started Jun 2020; status: recruiting.
02
Drugs
sigvotatug vedotin
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)breast cancerEsophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT04389632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04389632.